AuthorisedTherapeutic exploratory (Phase II)Interventional

CHARACTERIZATION OF ASTROCYTE REACTIVITY WITH [18F]F-DED PET IN NEURODEGENERATIVE DISEASES

This research is investigating a new brain scan method for people living with specific brain conditions, including different types of dementia and a genetic condition called CADASIL. Scientists want to understand how certain brain cells, called astrocytes, respond in these diseases. They will use a special tracer called [18F]DED, which can be seen in a PET scan, to look at these cells. The study is in an early stage (Phase II), meaning it’s exploring if this scanning method can provide useful information. The goal is to learn more about how these conditions affect the brain, which could eventually lead to better ways to diagnose and treat them.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Barcelonabeta Brain Research Center

Enrolment target

300

Start

24 Mar 2026

What is this study about?

This study is a research project focusing on understanding specific brain conditions, including different types of dementia and a genetic disorder called CADASIL. Dementia affects memory, thinking, and daily activities, while CADASIL is a rare inherited disease that can cause strokes and brain damage.

The main aim is to investigate cells in the brain known as astrocytes. These cells usually support and protect brain cells, but in some brain conditions, they can become overactive or change their behaviour. Researchers want to use a new type of brain scan called a PET scan with a special tracer, or dye, named [18F]DED, to see how these astrocytes are behaving in people with these conditions. The tracer helps them light up during the scan.

By looking at how astrocytes change, scientists hope to gain a better understanding of what happens in the brains of people with these diseases. This understanding is crucial because it could eventually help doctors diagnose these conditions earlier, monitor how they progress, and develop new treatments in the future. This is an exploratory study, meaning it’s a vital step in learning more about these complex diseases.

Key takeaways

This study explores a new brain scan for dementia and CADASIL.
It focuses on 'astrocytes', important brain support cells.
A special tracer called [18F]DED helps researchers see these cells.
The aim is to better understand these brain diseases.
It's a Phase II study, meaning it's an early-stage investigation.
Participation could help future diagnosis and treatment development.

Who may be eligible?

To take part in this study, you need to be at least 18 years old. There is no upper age limit, so people of all adult ages are welcome.

While the study is open to both men and women, specific health conditions are being looked at. These include different forms of dementia, such as Alzheimer's disease (both early-onset and late-onset forms, as well as inherited types), and a condition called CADASIL.

The research team will carefully check other specific medical details to ensure the study is safe and appropriate for everyone involved. If you have one of these conditions and are interested, they will explain all the requirements in detail.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of dementia (e.g., Alzheimer's) or CADASIL?
Are you generally able to attend appointments at a research centre?
Are you willing to undergo a PET scan?
Are you comfortable receiving an injection with a special tracer?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would undergo a special type of brain scan called a PET scan. Before the scan, a small amount of a special tracer called [18F]DED would be given to you. This tracer helps researchers see specific things in your brain during the scan.

The study would involve a few visits to a research clinic or hospital. These visits would likely include initial health checks, blood tests, and the PET scan itself. There wouldn't be any new medication to take as part of this study, other than the tracer used for the scan. The research team will explain exactly what each visit involves, how long it will take, and whether there are any follow-up appointments. The total duration of your participation would be fully explained before you agree to join.

Potential risks and benefits

Taking part in this study might offer a chance to contribute to our understanding of brain conditions and potentially help develop future treatments, though it will not directly treat your condition. As with any medical procedure, there are potential risks, such as side effects from the tracer or discomfort during scans. The study team will explain all known risks. Remember, your participation is completely voluntary; you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Spain

Common questions

What is a PET scan?

A PET scan is a special type of imaging test that shows how your organs and tissues are working. For this study, it helps doctors see specific activity in your brain.

What is an astrocyte?

Astrocytes are star-shaped cells in your brain that support nerve cells. Researchers are interested in how they behave in certain brain conditions.

Will this study cure my condition?

No, this study is about understanding brain conditions better, not about directly treating or curing them. It's an important step for future research.

How long will my involvement last?

The study team will tell you the exact duration, including how many visits and scans are involved, before you agree to participate.

Is the tracer ([18F]DED) safe?

The tracer is given in very small, carefully controlled amounts. The research team will explain any potential effects and safety information in detail.